{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:09:17Z","timestamp":1777950557000,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"St Joseph's Healthcare Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10549-026-07953-1","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:14:46Z","timestamp":1775117686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"217","author":[{"given":"Amber O.","family":"Molnar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Bota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaffa","family":"Romain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Som D.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"4","key":"7953_CR1","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1681\/ASN.2017070812","volume":"29","author":"J Sjaarda","year":"2018","unstructured":"Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Par\u00e9 G (2018) Blood HER2 and uromodulin as causal mediators of CKD. J Am Soc Nephrol 29(4):1326\u20131335","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"7953_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1524-6175.2002.01641.x","volume":"4","author":"GL Bakris","year":"2002","unstructured":"Bakris GL, Weir M (2002) ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what\u2019s the evidence. J Clin Hypertens (Greenwich) 4(6):420\u2013423","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"7953_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P et al (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135(2):73\u201387","journal-title":"Ann Intern Med"},{"issue":"3","key":"7953_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2019.04.012","volume":"96","author":"H Li","year":"2019","unstructured":"Li H, Shao F, Qian B, Sun Y, Huang Z, Ding Z, Dong L, Chen J, Zhang J, Zang Y (2019) Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis. Kidney Int 96(3):674\u2013688","journal-title":"Kidney Int"},{"issue":"5","key":"7953_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clbc.2022.03.004","volume":"22","author":"VR Marczyk","year":"2022","unstructured":"Marczyk VR, Rosa DD, Maia AL, Goemann IM (2022) Overall survival for HER2-positive breast cancer patients in the HER2-targeted era: evidence from a population-based study. Clin Breast Cancer 22(5):418\u2013423","journal-title":"Clin Breast Cancer"},{"issue":"Suppl 2","key":"7953_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S M\u00e9nard","year":"2001","unstructured":"M\u00e9nard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2):67\u201372","journal-title":"Oncology"},{"issue":"5","key":"7953_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125620","volume":"10","author":"SG Nicholls","year":"2015","unstructured":"Nicholls SG, Quach P, von Elm E, Guttmann A, Moher D, Petersen I, Sorensen HT, Smeeth L, Langan SM, Benchimol EI (2015) The REporting of studies conducted using observational routinely-collected health data (RECORD) statement: methods for arriving at consensus and developing reporting guidelines. PLoS One 10(5):e0125620","journal-title":"PLoS One"},{"issue":"5","key":"7953_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","volume":"41","author":"SC Robles","year":"1988","unstructured":"Robles SC, Marrett LD, Clarke EA, Risch HA (1988) An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41(5):495\u2013501","journal-title":"J Clin Epidemiol"},{"key":"7953_CR9","doi-asserted-by":"crossref","unstructured":"Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E: Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada. Clinical breast cancer 2025.","DOI":"10.1016\/j.clbc.2025.07.013"},{"issue":"19","key":"7953_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71288","volume":"14","author":"O Fatiregun","year":"2025","unstructured":"Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E (2025) Impact of immigration status on survival among stage 1 and 2 HER2-positive and triple-negative breast cancer in Ontario, Canada. Cancer Med 14(19):e71288","journal-title":"Cancer Med"},{"issue":"2","key":"7953_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-024-07282-1","volume":"206","author":"A Roberts","year":"2024","unstructured":"Roberts A, Hallet J, Nguyen L, Coburn N, Wright FC, Gandhi S, Jerzak K, Eisen A, Look Hong NJ (2024) Neoadjuvant chemotherapy for triple-negative and HER2 +ve breast cancer: striving for the standard of care. Breast Cancer Res Treat 206(2):227\u2013244","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7953_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100428","volume":"7","author":"S Morganti","year":"2022","unstructured":"Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, Criscitiello C (2022) How i treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? ESMO Open 7(2):100428","journal-title":"ESMO Open"},{"issue":"19","key":"7953_CR13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M et al (2021) New creatinine- and Cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749","journal-title":"N Engl J Med"},{"issue":"3","key":"7953_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40620-024-01887-x","volume":"37","author":"M Provenzano","year":"2024","unstructured":"Provenzano M, Hu L, Abenavoli C, Cianciolo G, Coppolino G, De Nicola L, La Manna G, Comai G, Baraldi O (2024) Estimated glomerular filtration rate in observational and interventional studies in chronic kidney disease. J Nephrol 37(3):573\u2013586","journal-title":"J Nephrol"},{"issue":"6","key":"7953_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J (2014) GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64(6):821\u2013835","journal-title":"Am J Kidney Dis"},{"issue":"4s","key":"7953_CR16","first-page":"S117","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international 105(4s):S117-s314","journal-title":"Kidney international"},{"key":"7953_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38:1228\u20131234","journal-title":"Commun Stat Simul Comput"},{"issue":"9897","key":"7953_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021\u20131028","journal-title":"Lancet"},{"issue":"9555","key":"7953_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29\u201336","journal-title":"Lancet"},{"key":"7953_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.breast.2020.10.003","volume":"54","author":"P Stewart","year":"2020","unstructured":"Stewart P, Blanchette P, Shah PS, Ye XY, Boldt RG, Fernandes R, Vandenberg T, Raphael J (2020) Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. Breast 54:203\u2013210","journal-title":"Breast"},{"issue":"4","key":"7953_CR21","volume":"2012","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D\u2019Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012(4):Cd006243","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"7953_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2042098614529603","volume":"5","author":"AA Onitilo","year":"2014","unstructured":"Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5(4):154\u2013166","journal-title":"Ther Adv Drug Saf"},{"issue":"11","key":"7953_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"5","key":"7953_CR24","first-page":"655","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity in adult cancer patients: JACC: cardio oncology state-of-the-art review. JACC: CardioOncology 6(5):655\u2013677","journal-title":"JACC: CardioOncology"},{"issue":"11","key":"7953_CR25","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41416-025-03190-3","volume":"133","author":"JS Lees","year":"2025","unstructured":"Lees JS, Fu EL, Faucon AL, Elyan BM, Inker LA, Levey AS, Jones RJ, Wilson RH, Mark PB, Carrero JJ (2025) Accuracy of glomerular filtration rate estimates among patients with cancer. Br J Cancer 133(11):1652\u20131659","journal-title":"Br J Cancer"},{"issue":"8","key":"7953_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734","journal-title":"N Engl J Med"},{"issue":"2","key":"7953_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A et al (2012) Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119","journal-title":"N Engl J Med"},{"issue":"3","key":"7953_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","volume":"18","author":"SM Swain","year":"2013","unstructured":"Swain SM, Ewer MS, Cort\u00e9s J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J (2013) Cardiac tolerability of Pertuzumab plus Trastuzumab plus Docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18(3):257\u2013264","journal-title":"Oncologist"},{"issue":"5","key":"7953_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11739-012-0794-9","volume":"7","author":"G Russo","year":"2012","unstructured":"Russo G, Cioffi G, Di Lenarda A, Tuccia F, Bovelli D, Di Tano G, Alunni G, Gori S, Faggiano P, Tarantini L (2012) Role of renal function on the development of cardiotoxicity associated with Trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 7(5):439\u2013446","journal-title":"Intern Emerg Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07953-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:36:23Z","timestamp":1777880183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07953-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7953"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07953-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AOM receives funding from the McMaster University Department of Medicine. AK administers funding from Amgen Canada and Janssen Canada to support the University Health Network Onco-Nephrology Fellowship Program.  MW is supported by a salary support award from the Population Health Research Institute and is an employee of the Ontario Renal Network of Ontario Health. SDM and DL have no relevant disclosures related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is an observational study. The use of data in this project was authorized under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act, which did not require review by a Research Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"10"}}